Strengthened glycolysis under hypoxia supports tumor symbiosis and hexosamine biosynthesis in pancreatic adenocarcinoma

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 10, 2013, Pages 3919-3924

  Guillaumond, Fabienne ^a,b,c,d   Leca, Julie ^a,b,c,d   Olivares, Orianne ^a,b,c,d   Lavaut, Marie Noëlle ^a,b,c,d   Vidal, Nicolas ^e   Berthezène, Patrice ^a,b,c,d   Dusetti, Nelson Javier ^a,b,c,d   Loncle, Céline ^a,b,c,d   Calvo, Ezequiel ^f   Turrini, Olivier ^b   Iovanna, Juan Lucio ^a,b,c,d   Tomasini, Richard ^a,b,c,d   Vasseur, Sophie ^a,b,c,d  

^a INSERM   (France)

^b INSTITUT PAOLI CALMETTES   (France)

^c CNRS   (France)

^d AIX MARSEILLE UNIVERSITY   (France)

^e AIX MARSEILLE UNIV   (France)

^f Oncology and Molecular Endocrinology Research Center   (Canada)

Author keywords

Glutamate; Malignancy; Metabolism; Pancreas

Indexed keywords

GLUCOSE; GLUTAMINE; GLYCOSYLATED PROTEIN; HEXOSAMINE; LACTIC ACID; N ACETYLGLUCOSAMINE; TUMOR MARKER;

AMINO ACID METABOLISM; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOSYNTHESIS; CANCER GROWTH; CANCER SURVIVAL; CARCINOMA CELL; CELL GROWTH; CELL HYPOXIA; CELL SURVIVAL; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM CELL; GENETIC TRANSCRIPTION; GLUCOSE METABOLISM; GLYCOLYSIS; HUMAN; HUMAN TISSUE; MALE; MOUSE; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN MODIFICATION; SYMBIOSIS;

ANIMALS; ANOXIA; CARCINOMA, PANCREATIC DUCTAL; CELL HYPOXIA; CELL LINE, TUMOR; CELL SURVIVAL; DISEASE MODELS, ANIMAL; GLUTAMINE; GLYCOLYSIS; HEXOSAMINES; HUMANS; LACTIC ACID; MALE; METABOLIC NETWORKS AND PATHWAYS; MICE; MICE, NUDE; MICE, TRANSGENIC; MODELS, BIOLOGICAL; PANCREATIC NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS;

EID: 84874614138     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1219555110     Document Type: Article

References (28)

1. Neesse A, et al. (2011) Stromal biology and therapy in pancreatic cancer. Gut 60(6): 861-868.
2. Koong AC, et al. (2000) Pancreatic tumors show high levels of hypoxia. Int J Radiat Oncol Biol Phys 48(4):919-922.
3. Bristow RG, Hill RP (2008) Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat Rev Cancer 8(3):180-192.
4. Graeber TG, et al. (1996) Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379(6560):88-91.
5. Yun J, et al. (2009) Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science 325(5947):1555-1559.
6. Chiche J, Brahimi-Horn MC, Pouysségur J (2010) Tumour hypoxia induces a metabolic shift causing acidosis: A common feature in cancer. J Cell Mol Med 14(4):771-794.
7. Semenza GL (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3(10):721-732.
8. Wise DR, et al. (2011) Hypoxia promotes isocitrate dehydrogenase- dependent carboxylation of α-ketoglutarate to citrate to support cell growth and viability. Proc Natl Acad Sci USA 108(49):19611-19616.
9. Metallo CM, et al. (2012) Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature 481(7381):380-384.
10. Le A, et al. (2012) Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells. Cell Metab 15(1):110-121.
11. Zhou W, et al. (2012) Proteomic analysis reveals Warburg effect and anomalous metabolism of glutamine in pancreatic cancer cells. J Proteome Res 11(2):554-563.
12. Ying H, et al. (2012) Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 149(3):656-670.
13. Chaika NV, et al. (2012) MUC1 mucin stabilizes and activates hypoxia-inducible factor 1 alpha to regulate metabolism in pancreatic cancer. Proc Natl Acad Sci U S A 109(34): 13787-13792.
14. Aguirre AJ, et al. (2003) Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev 17(24):3112-3126.
15. Cannito S, et al. (2008) Redox mechanisms switch on hypoxia-dependent epithelialmesenchymal transition in cancer cells. Carcinogenesis 29(12):2267-2278.
16. Sonveaux P, et al. (2008) Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest 118(12):3930-3942.
17. Kennedy KM, Dewhirst MW (2010) Tumor metabolism of lactate: The influence and therapeutic potential for MCT and CD147 regulation. Future Oncol 6(1):127-148.
18. Metallo CM, Vander Heiden MG (2010) Metabolism strikes back: Metabolic flux regulates cell signaling. Genes Dev 24(24):2717-2722.
19. Simard EP, Ward EM, Siegel R, Jemal A (2012) Cancers with increasing incidence trends in the United States: 1999 through 2008. CA Cancer J Clin 62(2):118-128.
20. Schwartz DL, et al. (2010) Radiosensitization and stromal imaging response correlates for the HIF-1 inhibitor PX-478 given with or without chemotherapy in pancreatic cancer. Mol Cancer Ther 9(7):2057-2067.
21. Gatenby RA, Gillies RJ (2004) Why do cancers have high aerobic glycolysis? Nat Rev Cancer 4(11):891-899.
22. Schneiderhan W, et al. (2009) CD147 silencing inhibits lactate transport and reduces malignant potential of pancreatic cancer cells in in vivo and in vitro models. Gut 58(10):1391-1398.
23. Gaglio D, et al. (2011) Oncogenic K-Ras decouples glucose and glutamine metabolism to support cancer cell growth. Mol Syst Biol 7:523.
24. Olivier-Van Stichelen S, et al. (2012) The hexosamine biosynthetic pathway and O-GlcNAcylation drive the expression of β-catenin and cell proliferation. Am J Physiol Endocrinol Metab 302(4):E417-E424.
25. Slawson C, Copeland RJ, Hart GW (2010) O-GlcNAc signaling: A metabolic link between diabetes and cancer? Trends Biochem Sci 35(10):547-555.
26. Hanover JA, Krause MW, Love DC (2012) Bittersweet memories: Linking metabolism to epigenetics through O-GlcNAcylation. Nat Rev Mol Cell Biol 13(5):312-321.
27. Yi W, et al. (2012) Phosphofructokinase 1 glycosylation regulates cell growth and metabolism. Science 337(6097):975-980.
28. Chirgwin JM, Przybyla AE, MacDonald RJ, Rutter WJ (1979) Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry 18(24): 5294-5299.